论文部分内容阅读
Background: Irinotecan (SN38) and oxaliplatin-being part of FOLFIRI or XELOX/ FOLFOX treatment protocols, respectively-are commonly used in the treatment of colorectal cancer patients.However, the frequent development of resistance to these drugs represents a considerable challenge in the clinic.